Reaction

Eye Oedema reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,424 reports · 44 co-occurring drugs

As of the last recalculation, Eye Oedema appears in 2,424 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 30.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	92	30.9	31.0
Avapritinib	42	30.3	30.4
Aflibercept	76	21.6	21.6
Imatinib Mesylate	59	18.6	18.6
Dorzolamide Hydrochloride And Timolol Maleate	15	16.4	16.4
Faricimab	11	11.7	11.7
Latanoprost	50	8.7	8.7
Carboxymethylcellulose Sodium	9	8.3	8.3
Moxifloxacin Hydrochloride	19	8.1	8.1
Cenegermin-Bkbj	11	7.8	7.8
Prednisolone Acetate	9	7.5	7.5
Tobramycin Sulfate	10	7.0	7.0
Imatinib	14	6.8	6.9
Infliximab-Dyyb	23	6.8	6.8
Dofetilide	8	6.6	6.6
Tobramycin	17	6.1	6.1
Brinzolamide	6	5.9	5.9
Brimonidine Tartrate	12	5.8	5.8
Tobramycin Solution	8	5.7	5.7
Timolol	8	5.7	5.7
Sunitinib Malate	25	5.5	5.5
Omalizumab	52	5.3	5.3
Timolol Maleate	6	5.2	5.2
Iohexol	5	5.2	5.2
Cetirizine Hydrochloride Allergy	18	5.1	5.1
Cetirizine Hydrochloride Tablets	18	5.1	5.1
Insulin Glargine-Yfgn	13	5.1	5.1
Sofosbuvir	11	4.8	4.8
Amlodipine Besylate And Valsartan	6	4.7	4.7
Insulin Human	21	4.6	4.6
Iron Sucrose	5	4.5	4.5
Encorafenib	5	4.3	4.3
Botulinum Toxin Type A	6	4.2	4.2
Travoprost	4	4.0	4.0
Bimatoprost	12	3.6	3.6
Trametinib	10	3.6	3.6
Dabrafenib	8	3.3	3.3
Lifitegrast	6	3.2	3.2
Siponimod	3	2.9	2.9
Cortisone Acetate	4	2.8	2.8
Crizotinib	4	2.7	2.7
Onabotulinumtoxina	23	2.6	2.6
Dasatinib	10	2.3	2.3
Ambrisentan	32	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.